Terazosin detailed information

Terazosin detailed information

File:Terazosin.svg
Clinical data
ATC code	G04CA03 (WHO)
Pharmacokinetic data
Protein binding	90-94%
Elimination half-life	12 hours
Identifiers
IUPAC name [4-(4-amino-6,7-dimethoxy-quinazolin-2-yl) piperazin-1-yl]- tetrahydrofuran-2-yl-methanone
CAS Number	63590-64-7
PubChem CID	5401
DrugBank	APRD00667
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}
Chemical and physical data
Formula	C19H25N5O4
Molar mass	387.433 g/mol

Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.

Terazosin (Hytrin) is a selective alpha 1 antagonist used for treatment of symptoms of an enlarged prostate (BPH). It also acts to lower the blood pressure, and is therefore a drug of choice for men with hypertension and prostate enlargement.

It works by blocking the action of adrenaline on smooth muscle of the bladder and the blood vessel walls.

Most common side effects include dizziness, drowsiness, headache, constipation, loss of appetite, fatigue, nasal congestion or dry eyes, but they generally go away after only a few days of use. Therapy should always be started with a low dose to avoid first dose phenomenon. Sexual side effects are rare, but may include priapism or erectile dysfunction.